IVD China last week: Beckman Coulter and Health Genetech, Roche Diagnostics, Sansure Biotech, Canhelp Genomics

Beckman Coulter and Health Genetech Forge a Strategic Partnership in Ningbo

On January 8, Health Genetech and Beckman Coulter entered into a strategic cooperation agreement, aiming to drive localized innovation and advanced R&D in the Chinese healthcare market. The partnership aims to deliver more efficient and precise diagnostic solutions to the Chinese healthcare market. Through Beckman Coulter's technological support and strategic investment, Health Genetech will accelerate the development and production of diagnostic products tailored to the needs of the Chinese market, contributing to the high-quality growth of the in-vitro diagnostics industry in China.

Roche Diagnostics’ VENTANA FOLR1 Antibody Test Gains NMPA Approval

Roche Diagnostics recently received NMPA approval for its VENTANA FOLR1 (FOLR1-2.1) antibody testing reagent, which uses immunohistochemistry to identify candidates for ELAHERE® (mirvetuximab soravtansine) treatment. This approval follows ELAHERE’s entry into the Chinese market in November 2024. The reagent, now recognized by the FDA, CE, and NMPA, becomes the first globally approved companion diagnostic for mirvetuximab soravtansine, providing critical support in treating epithelial ovarian cancer and related conditions.

Sansure Biotech's Strategic Acquisition: A Milestone Worth 8 Billion RMB

On January 10, Sansure Biotech announced its plan to acquire 100% equity in Zhongshan Weiming Haiji Biopharmaceutical Co., Ltd. for RMB 8.075 billion. Upon completion of the transaction, Zhongshan Haiji will become a wholly-owned subsidiary of the company.

Canhelp Genomics Teams Up with Italy’s Quimark to Transform European Precision Medicine

Recently, Hangzhou Canhelp Genomics Co., Ltd. announced a strategic partnership with Quimark, an innovative diagnostic company based in Italy. This collaboration will deeply integrate the technical expertise and business resources of both parties to provide innovative genetic testing products, including the Canhelp-Origin test for identifying the origin of tumor tissues and the Canhelp-UriBLAD non-invasive test for urothelial carcinoma, to cancer patients in Italy. The partnership aims to advance precision medicine, improving patients' quality of life and extending their survival.